EUVIMEDEUVIMED entdecken
Open Access

A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy

Charles T Lee, Olufela Koleoso, Mengying Deng, Iavor Veltchev, Teh Lin, Mark A Hallman, Eric M Horwitz, J Karen Wong

Brachytherapy · 2023

DOI: 10.1016/j.brachy.2023.06.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2023. Verfasst von Charles T Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: charles.lee@fccc.edu. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We hypothesize rectal hydrogel spacer (RHS) improves rectal dosimetry in patients undergoing salvage high-dose-rate brachytherapy (HDR-BT) for intact, recurrent prostate cancer (PC). METHODS AND MATERIALS: A prospectively collected institutional database was queried for recurrent PC patients treated with salvage HDR-BT from September 2015 to November 2021. Patients were offered RHS beginning June 2019. Dosimetric variables were compared between RHS and no-RHS groups for the average of two fractions using Wilcoxon rank-sum tests. Primary outcomes were rectal volume receiving 75% of prescription dose (V75%) and prostate volume receiving 100% of prescription dose (V100%). Generalized estimating equation (GEE) model was used to evaluate the association between other planning variables and rectal V75%. RESULTS: Forty-one PC patients received salvage HDR-BT, of whom 20 had RHS. All patients received 2400cGy in 2 fractions. Median RHS volume was 6.2cm3 (Standard deviation [SD]: ± 3.5cm3). Median follow-up was 4 months and 17 months in the RHS and no-RHS groups, respectively. Median rectal V75% with and without RHS were 0.0cm3 (IQR: 0.0-0.0cm3) and 0.06cm3 (IQR: 0.0-0.14cm3), respectively (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyProstatic NeoplasmsMaleHumansHydrogelsRadiotherapy DosageRadiometryRectum

Stichwörter der Autor:innen

DosimetryHigh dose-rate brachytherapyProstate cancerRectal hydrogel spacerReirradiationSalvage therapy

Substanzen

Hydrogels

Autor:innen und Institutionen

  • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: charles.lee@fccc.edu.
  • Doctor of Osteopathic Medicine Program, Philadelphia College of Osteopathic Medicine, Philadelphia, PA.
  • Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA.
  • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Lee, C. T., Koleoso, O., Deng, M., Veltchev, I., Lin, T., Hallman, M. A., Horwitz, E. M., & Wong, J. K. (2023). A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy. Brachytherapy. https://doi.org/10.1016/j.brachy.2023.06.003

Vancouver

Lee CT, Koleoso O, Deng M, Veltchev I, Lin T, Hallman MA, et al. A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy. Brachytherapy. 2023. doi:10.1016/j.brachy.2023.06.003

BibTeX
@article{Lee2023,
  author = {Lee, Charles T and Koleoso, Olufela and Deng, Mengying and Veltchev, Iavor and Lin, Teh and Hallman, Mark A and Horwitz, Eric M and Wong, J Karen},
  title = {A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy},
  journal = {Brachytherapy},
  year = {2023},
  doi = {10.1016/j.brachy.2023.06.003}
}
Kostenlos starten →